These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 36322089)

  • 21. Efficacy and safety of neoadjuvant immunotherapy combined with chemoradiotherapy or chemotherapy in esophageal cancer: A systematic review and meta-analysis.
    Liu Y; Bao Y; Yang X; Sun S; Yuan M; Ma Z; Zhang W; Zhai Y; Wang Y; Men Y; Qin J; Xue L; Wang J; Hui Z
    Front Immunol; 2023; 14():1117448. PubMed ID: 36761760
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy in locally advanced esophageal cancer: An updated meta-analysis.
    Liang Z; Chen T; Li W; Lai H; Li L; Wu J; Zhang H; Fang C
    Medicine (Baltimore); 2024 Jan; 103(3):e36785. PubMed ID: 38241577
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and Efficacy of Neoadjuvant Immune Checkpoint Inhibitor Therapy in Patients with Resectable Non-small-Cell Lung Cancer: A Systematic Review.
    Zhao Z; Gao Y; Xue Q; Gao S; He J
    Target Oncol; 2021 Jul; 16(4):425-434. PubMed ID: 33983556
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neoadjuvant immunotherapy for resectable hepatocellular carcinoma: a systematic review and meta-analysis.
    Han YH; Bo JQ; Liu LX
    Eur Rev Med Pharmacol Sci; 2023 Aug; 27(15):7134-7147. PubMed ID: 37606124
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: A prospective, single-arm, phase II study (TD-NICE).
    Yan X; Duan H; Ni Y; Zhou Y; Wang X; Qi H; Gong L; Liu H; Tian F; Lu Q; Sun J; Yang E; Zhong D; Wang T; Huang L; Wang J; Chaoyang Wang ; Wang Y; Wan Z; Lei J; Zhao J; Jiang T
    Int J Surg; 2022 Jul; 103():106680. PubMed ID: 35595021
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of neoadjuvant immunotherapy plus chemotherapy versus chemotherapy alone for patients with locally advanced esophageal squamous cell carcinoma: A propensity score matching.
    Jing SW; Zhai C; Zhang W; He M; Liu QY; Yao JF; Wang R; Tian ZQ; Wang J; Liu JF
    Front Immunol; 2022; 13():970534. PubMed ID: 36275724
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of neoadjuvant immunotherapy in resectable nonsmall cell lung cancer: A meta-analysis.
    Jia XH; Xu H; Geng LY; Jiao M; Wang WJ; Jiang LL; Guo H
    Lung Cancer; 2020 Sep; 147():143-153. PubMed ID: 32717571
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of neoadjuvant immunotherapy and traditional neoadjuvant therapy for resectable esophageal cancer: a systematic review and single-arm and network meta-analysis.
    Wang H; Song C; Zhao X; Deng W; Dong J; Shen W
    Front Immunol; 2023; 14():1170569. PubMed ID: 37251393
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of neoadjuvant nab-paclitaxel plus immunotherapy versus paclitaxel plus immunotherapy for esophageal squamous cell carcinoma.
    Yang Y; Li H; Chen X; Qin J; Li Y; Shen Y; Zhang R; Kang X; Wang Z; Zheng Q; Luo P; Li Y; He J
    Thorac Cancer; 2023 Mar; 14(7):700-708. PubMed ID: 36788648
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Perioperative immune checkpoint inhibitors combined with chemotherapy versus chemotherapy for locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: A systematic review and meta-analysis of randomized controlled trials.
    Huang D; Sun F; Ke L; Li S
    Int Immunopharmacol; 2024 Sep; 138():112576. PubMed ID: 38941672
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and efficacy of camrelizumab combined with radiotherapy as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma: a prospective single-arm phase II clinical trial protocol.
    Chen M; Huang Y; Zhang S; Zeng T; Huang G; Chen C; Zheng B
    Trials; 2023 Aug; 24(1):554. PubMed ID: 37626367
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunotherapy for Resectable Locally Advanced Esophageal Carcinoma.
    Fick CN; Dunne EG; Sihag S; Molena D; Cytryn SL; Janjigian YY; Wu AJ; Worrell SG; Hofstetter WL; Jones DR; Gray KD
    Ann Thorac Surg; 2024 Jul; 118(1):130-140. PubMed ID: 38408631
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Perioperative tislelizumab plus chemotherapy for locally advanced resectable thoracic esophageal squamous cell carcinoma trial: a prospective single-arm, phase II study (PILOT trial).
    Ding C; Guo Y; Zhou Y; He Y; Chen C; Zhang M; Guo X
    BMC Cancer; 2023 Dec; 23(1):1237. PubMed ID: 38102553
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Toripalimab Plus Paclitaxel and Carboplatin as Neoadjuvant Therapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma.
    He W; Leng X; Mao T; Luo X; Zhou L; Yan J; Peng L; Fang Q; Liu G; Wei X; Wang K; Wang C; Zhang S; Zhang X; Shen X; Huang D; Yi H; Bei T; She X; Xiao W; Han Y
    Oncologist; 2022 Feb; 27(1):e18-e28. PubMed ID: 35305102
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of neoadjuvant immunotherapy in surgically resectable esophageal cancer: A systematic review and meta-analysis.
    Wang Z; Shao C; Wang Y; Duan H; Pan M; Zhao J; Wang J; Ma Z; Li X; Yan X
    Int J Surg; 2022 Aug; 104():106767. PubMed ID: 35840049
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neoadjuvant immune checkpoint inhibitor in combination with chemotherapy or chemoradiotherapy in resectable esophageal cancer: A systematic review and meta-analysis.
    Wang H; Li S; Liu T; Chen J; Dang J
    Front Immunol; 2022; 13():998620. PubMed ID: 36177019
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neoadjuvant chemoradiotherapy combined with sequential perioperative toripalimab in locally advanced esophageal squamous cell cancer.
    Xu X; Sun Z; Liu Q; Zhang Y; Shen L; Zhang C; Lin H; Hu B; Rong L; Chen H; Wang X; Zhao X; Bai YR; Ye Q; Ma X
    J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38458635
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neoadjuvant chemoimmunotherapy for locally advanced esophageal squamous cell carcinoma: Data from literature review and a real-world analysis.
    Zhang Y; Li H; Yu B; Sun S; Hu Z; Wu X; Zhang Y; Li B; Zhang Y; Xiang J; Wang J; Yu H
    Thorac Cancer; 2024 May; 15(13):1072-1081. PubMed ID: 38532546
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Study on the efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy regimen for III-IVA esophageal squamous cell carcinoma post-surgery.
    Li C; Yu P; Li H; Yang X; Wang J; Jiang B
    J Cardiothorac Surg; 2024 Jan; 19(1):26. PubMed ID: 38273405
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Efficacy and safety of neoadjuvant chemotherapy combined with PD-1 antibody for esophageal squamous cell carcinoma in the real world].
    Wu PY; Wang T; Chen BJ; Shi MK; Huang B; Wu ND; Qi L; Chang XF; Wang LF; Liu BR; Ren W
    Zhonghua Zhong Liu Za Zhi; 2023 Feb; 45(2):170-174. PubMed ID: 36781239
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.